[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-disease-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-disease-risk":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100625271","cardiometabolic-risk-in-pregnancy-and-postpartum-100625271",false,"NCT07420465","Cardiometabolic Risk in Pregnancy and Postpartum","Inclusion Criteria:\n\n* Singleton pregnancy\n* 18 years and older\n* 3rd trimester of pregnancy at enrollment\n* Will be living in the area for the study duration\n* Women with or without pregnancy complications (e.g., gestational hypertension, preeclampsia, gestational diabetes)\n\nExclusion Criteria:\n\n* Multiple births\n* Diagnosed CVD or diabetes prior to pregnancy\n* Renal or other serious maternal diseases pre-pregnancy",true,"FEMALE","18 Years","45 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to evaluate changes in blood pressure and early cardiovascular risk markers and to determine whether a postpartum education intervention can improve cardiovascular risk monitoring among pregnant women in their third trimester through six months postpartum in Accra, Ghana. The study includes women aged 18 years and older with and without pregnancy-related cardiometabolic complications. Findings from this study will inform the development of scalable postpartum screening and intervention strategies to reduce long-term cardiovascular disease risk among women.",[27,28,29,30],"Hypertensive Disorders of Pregnancy","Postpartum Hypertension","Cardiovascular Disease Risk","High Blood Pressure","NOT_YET_RECRUITING","2026-02-11",{"date":34,"type":35},"2026-02-19","ACTUAL",{"date":37,"type":21},"2026-02",{"date":39,"type":21},"2027-12",{"name":41,"class":42},"Forgive Avorgbedor","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":15,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":5},"100591103","non-invasive-imaging-for-in-vivo-quantification-of-skin-composition-and-structure-100591103","NCT06976073","Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure","Spectrum1","Inclusion Criteria:\n\n* Adult patients part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.\n* Patients with signed informed consent\n\nExclusion Criteria:\n\n* Cognitive impairment\n* Patients unable to understand the oral and written study information in Swedish or English\n* Other severe disorder or terminal disease\n* Patients unable to provide an informed consent\n* Patient´s with damaged, scarred or non-intact skin within the skin area of interest.","ALL",{"count":53,"type":21},8000,"OBSERVATIONAL","The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population.\n\nThe main aims are:\n\n1. To evaluate the robustness of the technology for assessment of the molecular composition and structure of the skin tissue and microcirculatory function, on a prospective primary care population.\n2. To evaluate the device and method on its capability to detect deficiencies in circulation, compared with existing reference systems with similar characteristics for patients with known cardiovascular disease risk and\u002For diabetes.",[57,58,59,60,29],"Diabetes Mellitus, Type 2","Diabetic Foot","Peripheral Arterial Disease","Skin Cancer","RECRUITING","2025-05-08",{"date":64,"type":35},"2025-05-16",{"date":66,"type":35},"2023-02-01",{"date":68,"type":21},"2026-01-01",{"name":70,"class":71},"HJN Sverige AB\u002FNeko Health","INDUSTRY",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":43},"100504479","the-risc-registry--risk-informed-screening-registry-100504479","NCT05848856","The RISC Registry--Risk Informed Screening Registry","The Risk Informed Screening Registry (The RISC Registry)","RISC","Inclusion Criteria:\n\n* Female (Gender assigned at birth)\n* Unaffected women (by breast cancer, diabetes or cardiovascular disease)\n* Females who have been diagnosed with breast cancer, diabetes or cardiovascular disease\n* Females who are presenting for cancer, metabolic health or cardiovascular screening\n* Females presenting for mammography or other breast cancer screening procedures\n* Females presenting for cholesterol, other blood tests aimed at metabolic and cardiovascular health screening, ECG's, EKG's or other noninvasive scans for the presence of or risk of heart disease\n* Ages 18+\n* Willing to sign a study consent form\n* Willing to participate in PRO surveys\n* Willing to use technology to participate in the study procedures, if and as needed\n* Pregnant women may be included","100 Years",{"count":82,"type":21},10000,"Chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. Six in ten adults have one chronic disease; 4 in 10 have two or more. These are also leading drivers of the nation's $4.1 trillion in annual health care costs.\n\nCardiovascular disease is the number one cause of death for men and women, cancer is the second largest, with breast cancer being the second largest cause of death in women. Diabetes is the 8th highest cause of death for both men and women.\n\nRoutine screening, a focus on prevention, early detection, and patient engagement with proposed care plans, effective surveillance and follow up are some of the most effective ways to reduce the burden of chronic diseases across an individual's lifetime and at the population level.\n\nEstimating dollar costs associated with non-compliance with screening and health management recommendations is complex and variable depending on the specific context, disease, and condition. But there is much evidence to indicate that a significant amount of these annual costs can be mitigated if compliance with health management recommendations increases, and health problems are prevented or detected early.\n\nAccess to screening and noncompliance with health management recommendations impact the entire population, but more disparities exist in racial and ethnic minorities and in the historically underserved for cancer, obesity, diabetes and cardiovascular disease.\n\nThe overall cost of these disparities in the U.S. has been estimated at around 1.24 trillion U.S. Dollars.\n\nThe RISC Registry seeks to pursue the intersection of breast cancer, metabolic, and cardiovascular risk in women and study the application of individualized multi-condition risk assessments, risk-informed or personalized screening, prevention and follow up care approaches in a broad cross section of patients. It pursues the hypothesis that these approaches accompanied by population appropriate methods of clinician and patient engagement may increase understanding and compliance with breast cancer, obesity, and metabolic\u002Fcardiovascular\u002Fcardiometabolic risk screening, surveillance and follow up recommendations by empowering women to make healthier choices.\n\nIn doing so, these methods may identify ways to address disparities in screening and patient care and ultimately promote early detection or even reversal of adverse health conditions, improve overall personal health, and reduce overall health care costs.\n\nThe primary focus is cancer, cardiovascular and metabolic health screening with a focus on utilization of Precision Screening. (Precision Screening attempts to separate those who will benefit from screening from those that may not, through use of information on disease risk.)\n\nThe study will start by focusing on women and risk for these diseases and health conditions.",[85,29,86,87],"Breast Cancer Risk","Cardiometabolic Risk","Diabetes",[89,87,90,91,92,93,94,95,96],"Breast cancer","Obesity","Coronary artery disease","Risk","Prevention","Genetics","Social drivers of health","Personal risk adjusted screening plans","2024-07-09",{"date":99,"type":35},"2024-07-11",{"date":101,"type":21},"2024-09-01",{"date":103,"type":21},"2035-09-01",{"name":105,"class":42},"Precision Health Equity Initiative"]